Gradient Denervation Technologies, a Paris, France-based medical device company developing a minimally invasive device for the treatment of pulmonary hypertension, has raised €14M in Series A funding. The round was led by Asabys Partners through its new fund Sabadell Asabys II and was joined by Thuja Capital and Sofinnova Partners.
The company was founded in 2020 by CEO Martin Grasse and a team of engineers and clinicians from Stanford University. The Gradient device is a catheter-based system that uses ultrasound energy to ablate the nerves that control the pulmonary arteries. This reduces the constriction of the arteries and improves blood flow to the lungs. The Gradient device is still in the early stages of development, but the company has completed a successful first-in-human clinical trial. The company plans to use the funding to support further clinical trials and to bring the device to market.
The company's initial focus is on patients with Group 2 pulmonary hypertension, which is a type of pulmonary hypertension that occurs in people with heart failure. Group 2 pulmonary hypertension is a challenging condition to treat, and there are currently no approved therapies that can significantly improve patient outcomes. The Gradient device has the potential to be a breakthrough treatment for this patient population. The company's funding round is a significant milestone for the development of the Gradient device. The funding will allow the company to accelerate its clinical development program and bring the device to market sooner. This is good news for patients with Group 2 pulmonary hypertension, who are in desperate need of new treatment options.
